Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : The M77001 study group
Identifieur interne : 004422 ( PascalFrancis/Checkpoint ); précédent : 004421; suivant : 004423Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : The M77001 study group
Auteurs : Michel Marty [France, Italie, Australie, Royaume-Uni, Espagne, Irlande (pays), Suisse] ; Francesco Cognetti ; Dominique Maraninchi ; Ray Snyder ; Louis Mauriac ; Michèle Tubiana-Hulin ; Stephen Chan ; David Grimes ; Antonio Anton ; Ana Lluch ; John Kennedy ; Kenneth O'Byrne ; Pier Franco Conte ; Michael Green ; Carol Ward ; Karen Mayne ; Jean-Marc ExtraSource :
- Journal of clinical oncology [ 0732-183X ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Purpose This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Patients and Methods Patients were randomly assigned to six cycles of docetaxel 100 mg/m2 every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression. Results A total of 186 patients received at least one dose of the study drug. Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% v 34%; P = .0002), overall survival (median, 31.2 v 22.7 months; P = .0325), time to disease progression (median, 11.7 v 6.1 months; P = .0001), time to treatment failure (median, 9.8 v 5.3 months; P = .0001), and duration of response (median, 11.7 v 5.7 months; P = .009). There was little difference in the number and severity of adverse events between the arms. Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%). One patient in the combination arm experienced symptomatic heart failure (1%). Another patient experienced symptomatic heart failure 5 months after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 months. Conclusion Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.
Affiliations:
- Australie, Espagne, France, Irlande (pays), Italie, Royaume-Uni, Suisse
- Aquitaine, Latium, Nouvelle-Aquitaine, Provence-Alpes-Côte d'Azur, Victoria (État), Île-de-France
- Bordeaux, Marseille, Melbourne, Paris, Rome
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:05-0319825Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : The M77001 study group</title>
<author><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave-Roussy</wicri:noRegion>
<wicri:noRegion>Institut Gustave-Roussy</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Centre Rene Huguenin, Saint-Cloud, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Regina Elena Cancer Institute</s1>
<s2>Rome</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University Hospital</s1>
<s2>Modena</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>St Vincent's Hospital</s1>
<s2>Fitzroy</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>St Vincent's Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Wesley Medical Centre</s1>
<s2>Auchenflour</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Wesley Medical Centre</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Royal Melbourne Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Nottingham City Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Nottingham City Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Oncology, Leicester Royal Infirmary</s1>
<s2>Leicester</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Leicester</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Roche Products Limited</s1>
<s2>Welwyn Garden City</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Roche Products Limited</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Hospital Miguel Servet</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Hospital Miguel Servet</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Hospital Clinico Universitaire</s1>
<s2>Valencia</s2>
<s3>ESP</s3>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Hospital Clinico Universitaire</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>St James Hospital</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>St James Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>F. Hoffmann La Roche Ltd</s1>
<s2>Easel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann La Roche Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cognetti, Francesco" sort="Cognetti, Francesco" uniqKey="Cognetti F" first="Francesco" last="Cognetti">Francesco Cognetti</name>
</author>
<author><name sortKey="Maraninchi, Dominique" sort="Maraninchi, Dominique" uniqKey="Maraninchi D" first="Dominique" last="Maraninchi">Dominique Maraninchi</name>
</author>
<author><name sortKey="Snyder, Ray" sort="Snyder, Ray" uniqKey="Snyder R" first="Ray" last="Snyder">Ray Snyder</name>
</author>
<author><name sortKey="Mauriac, Louis" sort="Mauriac, Louis" uniqKey="Mauriac L" first="Louis" last="Mauriac">Louis Mauriac</name>
</author>
<author><name sortKey="Tubiana Hulin, Michele" sort="Tubiana Hulin, Michele" uniqKey="Tubiana Hulin M" first="Michèle" last="Tubiana-Hulin">Michèle Tubiana-Hulin</name>
</author>
<author><name sortKey="Chan, Stephen" sort="Chan, Stephen" uniqKey="Chan S" first="Stephen" last="Chan">Stephen Chan</name>
</author>
<author><name sortKey="Grimes, David" sort="Grimes, David" uniqKey="Grimes D" first="David" last="Grimes">David Grimes</name>
</author>
<author><name sortKey="Anton, Antonio" sort="Anton, Antonio" uniqKey="Anton A" first="Antonio" last="Anton">Antonio Anton</name>
</author>
<author><name sortKey="Lluch, Ana" sort="Lluch, Ana" uniqKey="Lluch A" first="Ana" last="Lluch">Ana Lluch</name>
</author>
<author><name sortKey="Kennedy, John" sort="Kennedy, John" uniqKey="Kennedy J" first="John" last="Kennedy">John Kennedy</name>
</author>
<author><name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name>
</author>
<author><name sortKey="Conte, Pier Franco" sort="Conte, Pier Franco" uniqKey="Conte P" first="Pier Franco" last="Conte">Pier Franco Conte</name>
</author>
<author><name sortKey="Green, Michael" sort="Green, Michael" uniqKey="Green M" first="Michael" last="Green">Michael Green</name>
</author>
<author><name sortKey="Ward, Carol" sort="Ward, Carol" uniqKey="Ward C" first="Carol" last="Ward">Carol Ward</name>
</author>
<author><name sortKey="Mayne, Karen" sort="Mayne, Karen" uniqKey="Mayne K" first="Karen" last="Mayne">Karen Mayne</name>
</author>
<author><name sortKey="Extra, Jean Marc" sort="Extra, Jean Marc" uniqKey="Extra J" first="Jean-Marc" last="Extra">Jean-Marc Extra</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0319825</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0319825 INIST</idno>
<idno type="RBID">Pascal:05-0319825</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004864</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001839</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">004422</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004422</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : The M77001 study group</title>
<author><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave-Roussy</wicri:noRegion>
<wicri:noRegion>Institut Gustave-Roussy</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Centre Rene Huguenin, Saint-Cloud, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Regina Elena Cancer Institute</s1>
<s2>Rome</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University Hospital</s1>
<s2>Modena</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>St Vincent's Hospital</s1>
<s2>Fitzroy</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>St Vincent's Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Wesley Medical Centre</s1>
<s2>Auchenflour</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Wesley Medical Centre</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Royal Melbourne Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Nottingham City Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Nottingham City Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Oncology, Leicester Royal Infirmary</s1>
<s2>Leicester</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Leicester</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Roche Products Limited</s1>
<s2>Welwyn Garden City</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Roche Products Limited</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Hospital Miguel Servet</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Hospital Miguel Servet</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Hospital Clinico Universitaire</s1>
<s2>Valencia</s2>
<s3>ESP</s3>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Hospital Clinico Universitaire</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>St James Hospital</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>St James Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>F. Hoffmann La Roche Ltd</s1>
<s2>Easel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>F. Hoffmann La Roche Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cognetti, Francesco" sort="Cognetti, Francesco" uniqKey="Cognetti F" first="Francesco" last="Cognetti">Francesco Cognetti</name>
</author>
<author><name sortKey="Maraninchi, Dominique" sort="Maraninchi, Dominique" uniqKey="Maraninchi D" first="Dominique" last="Maraninchi">Dominique Maraninchi</name>
</author>
<author><name sortKey="Snyder, Ray" sort="Snyder, Ray" uniqKey="Snyder R" first="Ray" last="Snyder">Ray Snyder</name>
</author>
<author><name sortKey="Mauriac, Louis" sort="Mauriac, Louis" uniqKey="Mauriac L" first="Louis" last="Mauriac">Louis Mauriac</name>
</author>
<author><name sortKey="Tubiana Hulin, Michele" sort="Tubiana Hulin, Michele" uniqKey="Tubiana Hulin M" first="Michèle" last="Tubiana-Hulin">Michèle Tubiana-Hulin</name>
</author>
<author><name sortKey="Chan, Stephen" sort="Chan, Stephen" uniqKey="Chan S" first="Stephen" last="Chan">Stephen Chan</name>
</author>
<author><name sortKey="Grimes, David" sort="Grimes, David" uniqKey="Grimes D" first="David" last="Grimes">David Grimes</name>
</author>
<author><name sortKey="Anton, Antonio" sort="Anton, Antonio" uniqKey="Anton A" first="Antonio" last="Anton">Antonio Anton</name>
</author>
<author><name sortKey="Lluch, Ana" sort="Lluch, Ana" uniqKey="Lluch A" first="Ana" last="Lluch">Ana Lluch</name>
</author>
<author><name sortKey="Kennedy, John" sort="Kennedy, John" uniqKey="Kennedy J" first="John" last="Kennedy">John Kennedy</name>
</author>
<author><name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name>
</author>
<author><name sortKey="Conte, Pier Franco" sort="Conte, Pier Franco" uniqKey="Conte P" first="Pier Franco" last="Conte">Pier Franco Conte</name>
</author>
<author><name sortKey="Green, Michael" sort="Green, Michael" uniqKey="Green M" first="Michael" last="Green">Michael Green</name>
</author>
<author><name sortKey="Ward, Carol" sort="Ward, Carol" uniqKey="Ward C" first="Carol" last="Ward">Carol Ward</name>
</author>
<author><name sortKey="Mayne, Karen" sort="Mayne, Karen" uniqKey="Mayne K" first="Karen" last="Mayne">Karen Mayne</name>
</author>
<author><name sortKey="Extra, Jean Marc" sort="Extra, Jean Marc" uniqKey="Extra J" first="Jean-Marc" last="Extra">Jean-Marc Extra</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antineoplastic agent</term>
<term>Breast cancer</term>
<term>Cancerology</term>
<term>Clinical trial</term>
<term>Docetaxel</term>
<term>First line treatment</term>
<term>Human</term>
<term>Human Epidermal growth factor Receptor 2</term>
<term>Malignant tumor</term>
<term>Mammary gland diseases</term>
<term>Metastasis</term>
<term>Monoclonal antibody</term>
<term>Phase II trial</term>
<term>Toxicity</term>
<term>Trastuzumab</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique phase II</term>
<term>Essai clinique</term>
<term>Efficacité traitement</term>
<term>Docétaxel</term>
<term>Toxicité</term>
<term>Trastuzumab</term>
<term>Métastase</term>
<term>Anticorps monoclonal</term>
<term>Homme</term>
<term>Glande mammaire pathologie</term>
<term>Stade avancé</term>
<term>Cancérologie</term>
<term>Tumeur maligne</term>
<term>Anticancéreux</term>
<term>Récepteur HER2</term>
<term>Cancer sein</term>
<term>Traitement première intention</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Patients and Methods Patients were randomly assigned to six cycles of docetaxel 100 mg/m<sup>2</sup>
every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression. Results A total of 186 patients received at least one dose of the study drug. Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% v 34%; P = .0002), overall survival (median, 31.2 v 22.7 months; P = .0325), time to disease progression (median, 11.7 v 6.1 months; P = .0001), time to treatment failure (median, 9.8 v 5.3 months; P = .0001), and duration of response (median, 11.7 v 5.7 months; P = .009). There was little difference in the number and severity of adverse events between the arms. Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%). One patient in the combination arm experienced symptomatic heart failure (1%). Another patient experienced symptomatic heart failure 5 months after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 months. Conclusion Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. oncol.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>19</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : The M77001 study group</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MARTY (Michel)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>COGNETTI (Francesco)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARANINCHI (Dominique)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SNYDER (Ray)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MAURIAC (Louis)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TUBIANA-HULIN (Michèle)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CHAN (Stephen)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GRIMES (David)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>ANTON (Antonio)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>LLUCH (Ana)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>KENNEDY (John)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>O'BYRNE (Kenneth)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>CONTE (Pier Franco)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>GREEN (Michael)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>WARD (Carol)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>MAYNE (Karen)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>EXTRA (Jean-Marc)</s1>
</fA11>
<fA14 i1="01"><s1>Institut Gustave-Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="02"><s1>Institut Paoli Calmettes</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="03"><s1>Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="04"><s1>Centre Rene Huguenin, Saint-Cloud, Institut Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="05"><s1>Regina Elena Cancer Institute</s1>
<s2>Rome</s2>
<s3>ITA</s3>
</fA14>
<fA14 i1="06"><s1>University Hospital</s1>
<s2>Modena</s2>
<s3>ITA</s3>
</fA14>
<fA14 i1="07"><s1>St Vincent's Hospital</s1>
<s2>Fitzroy</s2>
<s3>AUS</s3>
</fA14>
<fA14 i1="08"><s1>Wesley Medical Centre</s1>
<s2>Auchenflour</s2>
<s3>AUS</s3>
</fA14>
<fA14 i1="09"><s1>Royal Melbourne Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
</fA14>
<fA14 i1="10"><s1>Nottingham City Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="11"><s1>Department of Oncology, Leicester Royal Infirmary</s1>
<s2>Leicester</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="12"><s1>Roche Products Limited</s1>
<s2>Welwyn Garden City</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="13"><s1>Hospital Miguel Servet</s1>
<s2>Zaragoza</s2>
<s3>ESP</s3>
</fA14>
<fA14 i1="14"><s1>Hospital Clinico Universitaire</s1>
<s2>Valencia</s2>
<s3>ESP</s3>
</fA14>
<fA14 i1="15"><s1>St James Hospital</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
</fA14>
<fA14 i1="16"><s1>F. Hoffmann La Roche Ltd</s1>
<s2>Easel</s2>
<s3>CHE</s3>
</fA14>
<fA20><s1>4265-4274</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20094</s2>
<s5>354000132259910010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0319825</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Patients and Methods Patients were randomly assigned to six cycles of docetaxel 100 mg/m<sup>2</sup>
every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression. Results A total of 186 patients received at least one dose of the study drug. Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% v 34%; P = .0002), overall survival (median, 31.2 v 22.7 months; P = .0325), time to disease progression (median, 11.7 v 6.1 months; P = .0001), time to treatment failure (median, 9.8 v 5.3 months; P = .0001), and duration of response (median, 11.7 v 5.7 months; P = .009). There was little difference in the number and severity of adverse events between the arms. Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%). One patient in the combination arm experienced symptomatic heart failure (1%). Another patient experienced symptomatic heart failure 5 months after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 months. Conclusion Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Essai clinique phase II</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Phase II trial</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Docétaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Docetaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Docetaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Trastuzumab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Trastuzumab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Trastuzumab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Métastase</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Metastasis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Metástasis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Glande mammaire pathologie</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Stade avancé</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Advanced stage</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estadio avanzado</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>25</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Récepteur HER2</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Human Epidermal growth factor Receptor 2</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Cancer sein</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Breast cancer</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Traitement première intention</s0>
<s4>CD</s4>
<s5>98</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>First line treatment</s0>
<s4>CD</s4>
<s5>98</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Tratamiento primer línea</s0>
<s4>CD</s4>
<s5>98</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Anticytokine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Anticytokine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Anticitoquina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Antimitotique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Antimitotic</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Antimitótico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Taxane dérivé</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Taxane derivatives</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Taxane derivado</s0>
<s5>39</s5>
</fC07>
<fN21><s1>227</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Australie</li>
<li>Espagne</li>
<li>France</li>
<li>Irlande (pays)</li>
<li>Italie</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
</country>
<region><li>Aquitaine</li>
<li>Latium</li>
<li>Nouvelle-Aquitaine</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Victoria (État)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Bordeaux</li>
<li>Marseille</li>
<li>Melbourne</li>
<li>Paris</li>
<li>Rome</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Anton, Antonio" sort="Anton, Antonio" uniqKey="Anton A" first="Antonio" last="Anton">Antonio Anton</name>
<name sortKey="Chan, Stephen" sort="Chan, Stephen" uniqKey="Chan S" first="Stephen" last="Chan">Stephen Chan</name>
<name sortKey="Cognetti, Francesco" sort="Cognetti, Francesco" uniqKey="Cognetti F" first="Francesco" last="Cognetti">Francesco Cognetti</name>
<name sortKey="Conte, Pier Franco" sort="Conte, Pier Franco" uniqKey="Conte P" first="Pier Franco" last="Conte">Pier Franco Conte</name>
<name sortKey="Extra, Jean Marc" sort="Extra, Jean Marc" uniqKey="Extra J" first="Jean-Marc" last="Extra">Jean-Marc Extra</name>
<name sortKey="Green, Michael" sort="Green, Michael" uniqKey="Green M" first="Michael" last="Green">Michael Green</name>
<name sortKey="Grimes, David" sort="Grimes, David" uniqKey="Grimes D" first="David" last="Grimes">David Grimes</name>
<name sortKey="Kennedy, John" sort="Kennedy, John" uniqKey="Kennedy J" first="John" last="Kennedy">John Kennedy</name>
<name sortKey="Lluch, Ana" sort="Lluch, Ana" uniqKey="Lluch A" first="Ana" last="Lluch">Ana Lluch</name>
<name sortKey="Maraninchi, Dominique" sort="Maraninchi, Dominique" uniqKey="Maraninchi D" first="Dominique" last="Maraninchi">Dominique Maraninchi</name>
<name sortKey="Mauriac, Louis" sort="Mauriac, Louis" uniqKey="Mauriac L" first="Louis" last="Mauriac">Louis Mauriac</name>
<name sortKey="Mayne, Karen" sort="Mayne, Karen" uniqKey="Mayne K" first="Karen" last="Mayne">Karen Mayne</name>
<name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name>
<name sortKey="Snyder, Ray" sort="Snyder, Ray" uniqKey="Snyder R" first="Ray" last="Snyder">Ray Snyder</name>
<name sortKey="Tubiana Hulin, Michele" sort="Tubiana Hulin, Michele" uniqKey="Tubiana Hulin M" first="Michèle" last="Tubiana-Hulin">Michèle Tubiana-Hulin</name>
<name sortKey="Ward, Carol" sort="Ward, Carol" uniqKey="Ward C" first="Carol" last="Ward">Carol Ward</name>
</noCountry>
<country name="France"><noRegion><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</noRegion>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</country>
<country name="Italie"><region name="Latium"><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</region>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</country>
<country name="Australie"><noRegion><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</noRegion>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</noRegion>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</noRegion>
<name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</country>
<country name="Irlande (pays)"><noRegion><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Marty, Michel" sort="Marty, Michel" uniqKey="Marty M" first="Michel" last="Marty">Michel Marty</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004422 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 004422 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PascalFrancis |étape= Checkpoint |type= RBID |clé= Pascal:05-0319825 |texte= Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : The M77001 study group }}
This area was generated with Dilib version V0.6.33. |